Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:14 am
Author: Getaka|Social: XLinkedIn

Kwality Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹947.22Overvalued by 32.53%vs CMP ₹1,404.00

P/E (25.5) × ROE (16.2%) × BV (₹281.00) × DY (2.00%)

₹550.46Overvalued by 60.79%vs CMP ₹1,404.00
MoS: -155.1% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹814.8522%Over (-42%)
Graham NumberEarnings₹587.0616%Over (-58.2%)
Earnings PowerEarnings₹101.4511%Over (-92.8%)
DCFCash Flow₹435.6813%Over (-69%)
Net Asset ValueAssets₹281.387%Over (-80%)
EV/EBITDAEnterprise₹649.489%Over (-53.7%)
Earnings YieldEarnings₹545.107%Over (-61.2%)
ROCE CapitalReturns₹878.389%Over (-37.4%)
Revenue MultipleRevenue₹178.275%Over (-87.3%)
Consensus (9 models)₹550.46100%Overvalued
Key Drivers: Wide model spread (₹101–₹878) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -14.0%

*Investments are subject to market risks

Investment Snapshot

64
Kwality Pharmaceuticals Ltd scores 64/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health72/100 · Strong
ROCE 18.2% GoodROE 16.2% GoodD/E 0.57 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.50% (6mo) Slight increasePromoter holding at 54.8% Stable
Earnings Quality40/100 · Moderate
OPM contracting (31% → 22%) Declining
Quarterly Momentum90/100 · Strong
Revenue (4Q): +33% YoY AcceleratingProfit (4Q): +93% YoY Strong
Industry Rank55/100 · Moderate
P/E 25.5 vs industry 53.8 Cheaper than peersROCE 18.2% vs industry 16.4% Average3Y sales CAGR: -7% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:14 am

Market Cap 1,457 Cr.
Current Price 1,404
Intrinsic Value₹550.46
High / Low 1,740/666
Stock P/E25.5
Book Value 281
Dividend Yield0.00 %
ROCE18.2 %
ROE16.2 %
Face Value 10.0
PEG Ratio-1.82

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Kwality Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Kwality Pharmaceuticals Ltd 1,457 Cr. 1,404 1,740/66625.5 2810.00 %18.2 %16.2 % 10.0
Amrutanjan Health Care Ltd 1,444 Cr. 500 791/48625.0 1180.92 %22.4 %16.5 % 1.00
Beta Drugs Ltd 1,287 Cr. 1,270 2,000/99029.9 2190.00 %27.0 %25.9 % 10.0
Jagsonpal Pharmaceuticals Ltd 1,243 Cr. 186 302/15529.2 37.91.35 %23.0 %18.6 % 2.00
Lincoln Pharmaceuticals Ltd 1,191 Cr. 595 679/44013.6 3570.30 %17.3 %12.8 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Kwality Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 566967707892809084116111111123
Expenses 41575454617163706790878693
Operating Profit 15121415172117201826242530
OPM % 27%17%20%22%21%23%22%22%21%22%22%23%24%
Other Income 0-15001-7001101-0
Interest 2222332322332
Depreciation 4455554555555
Profit before tax 10-107810611131119171822
Tax % 28%-24%25%24%21%28%25%33%25%24%30%23%28%
Net Profit 7-7568488914121416
EPS in Rs 6.97-7.095.256.037.424.348.078.188.2313.9711.5013.6115.43

Last Updated: March 4, 2026, 2:46 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 7:46 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 60527695137165138261456251307370462
Expenses 56497086125149124231284190241290357
Operating Profit 446912151429172616780105
OPM % 6%7%8%9%8%9%10%11%38%24%22%22%23%
Other Income 010211424-14-522
Interest 1112223337101011
Depreciation 112233461115201820
Profit before tax 2236811112216226315477
Tax % 47%29%39%41%38%31%24%29%26%24%24%26%
Net Profit 11235881512019244057
EPS in Rs 0.951.321.893.314.517.288.1214.86115.7018.7623.1138.4454.51
Dividend Payout % 0%0%0%9%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%100.00%50.00%66.67%60.00%0.00%87.50%700.00%-84.17%26.32%66.67%
Change in YoY Net Profit Growth (%)0.00%100.00%-50.00%16.67%-6.67%-60.00%87.50%612.50%-784.17%110.48%40.35%

Kwality Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:22%
5 Years:22%
3 Years:-7%
TTM:26%
Compounded Profit Growth
10 Years:41%
5 Years:37%
3 Years:-31%
TTM:35%
Stock Price CAGR
10 Years:%
5 Years:73%
3 Years:34%
1 Year:19%
Return on Equity
10 Years:27%
5 Years:28%
3 Years:15%
Last Year:16%

Last Updated: September 5, 2025, 9:25 am

Balance Sheet

Last Updated: January 7, 2026, 3:59 pm

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 4455101010101010101010
Reserves 1315182121283752172192216255282
Borrowings 68131926283541549098112110
Other Liabilities 121017274140536510671747279
Total Liabilities 3538527298107135169343364398451481
Fixed Assets 111111161928425691120138144143
CWIP 000000031214000
Investments 3457988944444
Other Assets 21233650707186102236226256303335
Total Assets 3538527298107135169343364398451481

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -01-34-01262659424353
Cash from Investing Activity + -4-1-2-7-6-11-17-23-63-48-26-28
Cash from Financing Activity + 31555-212161-17-14
Net Cash Flow -2001-1-1142-5-010
Free Cash Flow -2-1-5-3-61-1234-41828
CFO/OP -11%33%-22%75%26%104%59%112%59%79%67%85%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-2.00-4.00-7.00-10.00-14.00-13.00-21.00-12.00118.00-29.00-31.00-32.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 416395879986805357107138154
Inventory Days 586154725434943897310187167
Days Payable 584061677952965863117106112
Cash Conversion Cycle 418589927468783391300219209
Working Capital Days 603541211921432562120103100
ROCE %12%11%15%19%19%21%18%26%97%18%16%18%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 54.73%54.73%54.76%54.76%54.82%54.82%54.82%54.82%54.82%54.82%54.82%54.82%
FIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.50%
DIIs 0.01%0.01%0.01%0.01%0.00%0.00%0.02%0.03%0.32%0.33%0.33%0.33%
Public 45.25%45.25%45.22%45.22%45.17%45.18%45.15%45.14%44.86%44.86%44.83%44.33%
No. of Shareholders 6,2116,9436,2915,7865,6955,2737,4878,9479,42010,11511,59510,709

Shareholding Pattern Chart

No. of Shareholders

Kwality Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 38.3622.7618.16115.6414.60
Diluted EPS (Rs.) 38.3622.7618.16115.6414.60
Cash EPS (Rs.) 55.9941.6133.00125.8920.61
Book Value[Excl.RevalReserv]/Share (Rs.) 253.70213.74191.08172.5056.91
Book Value[Incl.RevalReserv]/Share (Rs.) 254.47214.51191.85173.2757.68
Revenue From Operations / Share (Rs.) 356.77296.03241.93439.64252.51
PBDIT / Share (Rs.) 79.3265.6760.79168.8229.33
PBIT / Share (Rs.) 61.7046.8246.38158.5223.07
PBT / Share (Rs.) 52.1829.9724.65155.7120.50
Net Profit / Share (Rs.) 38.3622.7618.58115.5914.35
NP After MI And SOA / Share (Rs.) 38.4022.9318.67115.6414.60
PBDIT Margin (%) 22.2322.1825.1238.3911.61
PBIT Margin (%) 17.2915.8119.1636.059.13
PBT Margin (%) 14.6210.1210.1835.418.11
Net Profit Margin (%) 10.757.687.6826.295.68
NP After MI And SOA Margin (%) 10.767.747.7126.305.78
Return on Networth / Equity (%) 15.1310.659.6966.5325.09
Return on Capital Employeed (%) 23.0420.0421.1378.2127.21
Return On Assets (%) 8.906.035.4735.239.10
Long Term Debt / Equity (X) 0.050.080.130.110.30
Total Debt / Equity (X) 0.420.430.450.240.57
Asset Turnover Ratio (%) 0.870.820.721.791.73
Current Ratio (X) 1.671.601.651.751.35
Quick Ratio (X) 1.181.080.951.341.13
Inventory Turnover Ratio (X) 4.571.871.625.648.31
Interest Coverage Ratio (X) 8.336.5610.4860.0511.39
Interest Coverage Ratio (Post Tax) (X) 5.033.966.9542.116.57
Enterprise Value (Cr.) 997.78515.35400.57630.8185.72
EV / Net Operating Revenue (X) 2.701.681.601.380.32
EV / EBITDA (X) 12.127.566.353.602.82
MarketCap / Net Operating Revenue (X) 2.441.381.271.320.22
Price / BV (X) 3.431.901.603.340.96
Price / Net Operating Revenue (X) 2.441.381.271.320.22
EarningsYield 0.040.050.060.190.26

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Kwality Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 04/05/1983 and has its registered office in the State of Punjab, India. Company's Corporate Identification Number(CIN) is L24232PB1983PLC005426 and registration number is 005426. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 370.20 Cr. and Equity Capital is Rs. 10.38 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsVillage Nagkalan, Amritsar Punjab 143601Contact not found
Management
NamePosition Held
Mr. Ramesh AroraManaging Director
Mr. Aditya AroraWholeTime Director & CFO
Mrs. Anju AroraWhole Time Director
Mr. Ajay Kumar AroraWhole Time Director
Mrs. Geeta AroraWhole Time Director
Mr. Pankaj TakkarIndependent Director
Mr. Kartik KapurIndependent Director
Mr. Prashanth VellankiIndependent Director
Mr. Ravi Shanker SinghIndependent Director
Mr. Vinod Kumar SharmaIndependent Director

FAQ

What is the intrinsic value of Kwality Pharmaceuticals Ltd and is it undervalued?

As of 10 April 2026, Kwality Pharmaceuticals Ltd's intrinsic value is ₹550.46, which is 60.79% lower than the current market price of ₹1,404.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (16.2 %), book value (₹281), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Kwality Pharmaceuticals Ltd?

Kwality Pharmaceuticals Ltd is trading at ₹1,404.00 as of 10 April 2026, with a FY2026-2027 high of ₹1,740 and low of ₹666. The stock is currently in the middle of its 52-week range. Market cap stands at ₹1,457 Cr..

How does Kwality Pharmaceuticals Ltd's P/E ratio compare to its industry?

Kwality Pharmaceuticals Ltd has a P/E ratio of 25.5, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Kwality Pharmaceuticals Ltd financially healthy?

Key indicators for Kwality Pharmaceuticals Ltd: ROCE of 18.2 % indicates efficient capital utilization; ROE of 16.2 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Kwality Pharmaceuticals Ltd profitable and how is the profit trend?

Kwality Pharmaceuticals Ltd reported a net profit of ₹40 Cr in Mar 2025 on revenue of ₹370 Cr. Compared to ₹120 Cr in Mar 2022, the net profit shows a declining trend.

Does Kwality Pharmaceuticals Ltd pay dividends?

Kwality Pharmaceuticals Ltd has a dividend yield of 0.00 % at the current price of ₹1,404.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Kwality Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports